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Newborn screening is an important public health program and a triumph of preventive 19 
medicine. Economic analyses show that the benefits of newborn screening clearly outweigh the 20 
costs for certain diseases but not necessarily for other ones. This is due to the great diversity of the 21 
natural history of the diseases detected, to the fact that each of these diseases considered 22 
individually is rare, and to differences in the effectiveness of interventions. In addition, the benefit-23 
cost ratio of screening for a particular disorder may differ between countries, specifically between 24 
high-income and low- and middle-income countries. The burden of a disorder may also be 25 
alleviated by increased clinical awareness and effective clinical services, even in the absence of 26 
newborn screening. In this article, the authors focus on economic analyses of newborn screening 27 
for primary congenital hypothyroidism, which has been in place in high-income countries for 28 
roughly 40 years, and for classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency. 29 
Screening for the latter is not yet universal, even in high-income countries, although the lack of 30 
universal implementation may reflect factors other than economic considerations. 31 
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Laboratory-based newborn screening (NBS) on dried blood spots collected on filter paper, 34 
which began with the method developed by Guthrie and Susi [1] for phenylketonuria (PKU) in 35 
1963, is considered as one of the major advances in preventive medicine over the past half-century 36 
[2, 3]. NBS was originally justified as a publicly funded program by its ability to avoid the cost of 37 
institutional care for severely disabled individuals with untreated PKU. However, it is unclear what 38 
role has been played by the economic benefits of early detection in the establishment and 39 
maintenance of NBS for all the other diseases that can now be screened for. Ever since the time of 40 
Dr Guthrie, advocacy by parents and/or professionals has certainly played a major role in the 41 
adoption and expansion of NBS. 42 
Economic evaluations of health interventions can be either partial, looking just at costs, or 43 
full, reporting calculations of both costs and health consequences. For example, a partial economic 44 
evaluation of NBS might report the cost of screening and diagnostic testing per case detected but 45 
not the health impacts or downstream costs of screening. There are two main types of full economic 46 
evaluations, cost-effectiveness analysis (CEA) and cost-benefit analysis (CBA). CEAs calculate 47 
the sum of intervention and treatment costs with and without the intervention and compare the 48 
difference in total costs with the difference in health outcomes. A CBA converts all outcomes to 49 
monetary values. That includes health outcomes—by assigning monetary values to years of life 50 
gained and years of avoided illness. It can also include economic outcomes, such as increased 51 
economic productivity. 52 
Both CEAs and CBAs calculate “incremental” cost relative to the costs associated with a 53 
comparison strategy. For example, the cost of adding a disorder to a newborn screening panel does 54 
not include the fixed cost of the existing newborn screening infrastructure, but only those costs 55 
that change when a new disorder is added. In a CEA, analysts are expected to calculate the sums 56 
of costs and outcomes for the strategies that are being compared. If one strategy has better 57 
outcomes and lower costs than all other strategies (i.e., negative incremental costs), it is said to be 58 
the “dominant” strategy and is “cost-saving” [4].  59 
If net costs for a strategy with better outcomes are positive relative to the comparison, CEA 60 
analysts calculate the ratio of the incremental cost per unit of health outcome and report it as the 61 
incremental cost-effectiveness ratio or ICER. The denominator of the ICER can be life-years saved 62 
or quality-adjusted life-years (QALYs), a preference-based measure that combines improvements 63 
in both functioning and survival in terms of health utilities. A CEA that calculates outcomes in 64 
terms of QALYs can also be said to be a cost-utility analysis (CUA). If the ICER for a proposed 65 
strategy is favorable relative to that of accepted healthcare interventions, it is widely considered to 66 
be “cost-effective.”  67 
Full economic evaluations may differ in which types of costs are assessed. Economic 68 
evaluations conducted from the societal perspective typically include “indirect” or “productivity” 69 
costs. These include the lost economic output from affected individuals due to premature death 70 
and disability. In addition to complete disability, individuals may be limited in the type or amount 71 
of work they are able to perform. Productivity costs can also include the loss of earned income 72 




resulting from providing informal care to a disabled family member. Many CEAs and CBAs 73 
include estimates of productivity costs, but differences in methods can make it difficult to compare 74 
estimates [5, 6]. 75 
Congenital disorders such as congenital hypothyroidism (CH) and PKU can result in 76 
cognitive deficits, which range in severity from overt intellectual disability to milder deficits 77 
within the usual range of cognitive ability in the population. CEAs and CBAs often include the 78 
medical, educational, and residential costs of care associated with overt intellectual disability. 79 
Some also calculate the loss in lifetime economic output among persons with intellectual disability. 80 
Published CEAs or CBAs of NBS to date have not quantified the economic impact of milder 81 
cognitive deficits, unlike in environmental health [7]. 82 
NBS is conducted in numerous countries for two endocrine disorders, CH and classic 83 
congenital adrenal hyperplasia due to 21-hydroxylase deficiency (CAH). The latter is a single, 84 
lifelong, monogenic disorder with a clear pattern of autosomal recessive transmission and NBS 85 
has therefore not resulted in an increase in prevalence [8] (Table). By contrast, CH is 86 
heterogeneous, encompassing a group of disorders, some of which are monogenic and others are 87 
multifactorial in etiology [9]. Primary (or thyroidal) CH is the primary target of NBS because of 88 
clear evidence that early detection prevents intellectual disability. Depending on the screening 89 
protocol used, NBS programs may also detect cases of central CH, but because of lack of 90 
conclusive evidence of improved outcomes from early diagnosis, central CH is not a screening 91 
target in most NBS programs [10, 11]. 92 
CH may be either permanent or transient, and prevalence of permanent CH at age 3 years 93 
or later is substantially lower than CH prevalence during early infancy [12, 13]. Incomplete 94 
phenotyping through thyroid imaging and documentation of permanence of hypothyroidism 95 
hampers the assessment of causes and implications of primary CH [14] and overreliance on 96 
biochemical measures may lead to overdiagnosis at present [15]. 97 
Congenital hypothyroidism (CH) 98 
Quebec was the first place in the world where population screening for CH was established 99 
on April 1, 1974 [16]. For technical reasons, the biomarker often used initially as the primary test 100 
was thyroxine (T4), but this was replaced by thyroid stimulating hormone (TSH) in Quebec in 1987 101 
and subsequently in most other NBS programs [17]. It has been reported in a partial CEA from the 102 
Netherlands that a primary T4 testing strategy followed by TSH measurement in specimens with 103 
low T4 values, which can detect cases of both central and primary CH, is considerably less 104 
expensive than primary TSH testing [18]. However, the remainder of this article focuses on 105 
primary CH, the main target of most NBS programs. 106 
The positive predictive value (PPV) of a TSH concentration greater than 30 mU/L of whole 107 
blood on a sample obtained after 24 hours of life for a confirmed diagnosis of CH is 95% [19]. 108 
Since the implementation of NBS, about two thirds of newborns with confirmed overt CH have 109 
thyroid dysgenesis (either sublingual thyroid ectopy or athyreosis) [20, 21]. Prior to NBS, about 110 
30% of children with clinically diagnosed CH received special education due to intellectual 111 




disability [22, 23]. Since the implementation of NBS, this proportion has gradually decreased and 112 
is now no higher than that of the general population [24].  113 
Given the prevalence of CH, which is 4 to 8 times that of PKU, and the impact of NBS on 114 
the prevention of intellectual disability [23, 25], CH quickly became a model disease that illustrates 115 
the benefits of NBS. After about a decade of adding NBS for CH on the filter paper cards collected 116 
for PKU screening, it was estimated by several groups that the economic benefits of NBS for CH 117 
greatly exceeded its costs, with a ratio of 2.5-7.8 dollars in savings for every dollar spent on 118 
screening [26]. However, some estimates may have reflected unrealistic projections of the 119 
prevalence and cost of intellectual disability among children with CH [27]. Another economic 120 
analysis projected at least 2 dollars in averted education and productivity costs per dollar spent on 121 
screening [28]. 122 
The majority of CBAs of NBS for CH assumed that most children with CH experience 123 
intellectual disability if treated late or not at all. In contrast, a meta-analysis found that 28% of 124 
children with clinically diagnosed CH in unscreened cohorts had IQ <70 (the definition of 125 
intellectual disability used by the World Health Organization) [23]. In addition, as often happens 126 
with screening, implementation of NBS quickly led to an  increase in the number of children being 127 
diagnosed with CH, from one in 6,500-7,000 to one in 3,100 [12, 23]. A retrospective study in 128 
Sweden combined with systematic follow-up was able to assess cognitive and neurological 129 
development in 26 of 32 children who had a TSH on the stored NBS specimen > 40 mU/L. Of the 130 
26, 20 (one in 4,500) had permanent hypothyroidism diagnosed at age 5 y, 14 who had been 131 
clinically diagnosed and treated at a median age of 5 months (six after 12 months) and six who 132 
had not been diagnosed or treated prior to the study. The average cognitive ability among the 20 133 
children with permanent CH was 16 points lower relative to the six children who screened positive 134 
but were euthyroid at age 5 [12]. By subgroup, the average loss was 55 points for two children 135 
with intellectual disability, 14 points for 12 other children with clinical CH, and 7 points for six 136 
children with subclinical CH (Table). 137 
Among children with permanent CH diagnosed by NBS, delayed initiation of treatment 138 
beyond 21 days after birth was reported in one study to be associated with an average loss of 8 IQ 139 
points [29]. However, other studies did not find a significant association between age at initiation 140 
of treatment and cognitive test scores [30]. Because early initiation of high-dose levothyroxine 141 
treatment has been shown to normalize cognitive scores in most children with permanent CH 142 
diagnosed after NBS, it would be reasonable to include the economic gain in productivity 143 
associated with higher IQ scores within the usual range in future societal perspective economic 144 
evaluations of CH NBS.  145 
Over time, lowering TSH cut-offs and adding screening samples has predictably led to a 146 
further progressive increase in estimated prevalence of CH, typically more than one in 2,000 [14, 147 
19]. Very recently, a program even reported a prevalence of one in 911 births [15] - seven-fold 148 
higher than pre-NBS. Many of these children may have isolated hyperthyrotropinemia (transient 149 
or permanent) and not CH [31, 32]. Most additional infants diagnosed with permanent CH through 150 
lower screening cutoffs or repeat specimens have a normal thyroid anatomy [13, 21, 33, 34], and 151 
the benefit of early treatment for such children has not been demonstrated. Accurately projecting 152 




the economic benefits of NBS for CH to include all newborns diagnosed with CH is not currently 153 
feasible given the controversy about cognitive and educational outcomes for the complete 154 
spectrum of children diagnosed with CH through various NBS programs [35]. 155 
Children with CH or mild hyperthyrotropinemia at NBS may have behavioral or learning 156 
difficulties even if IQ is in the normal range [36, 37]. It appears that abnormal thyroid hormone 157 
status in a child is associated with a range of behavioral and developmental challenges, such as 158 
attention problems [38]. However, it is not established whether NBS and early diagnosis avoids 159 
those issues. 160 
Lastly, it is sobering to realize that 70% of the world’s newborns do not benefit from any 161 
NBS at all [17, 39]. In some low- and middle-income countries (LMICs), sending filter papers to 162 
a central laboratory may not be feasible because of a high proportion of home deliveries and 163 
transportation hurdles hampering same-day sample transfer to the laboratory. A bedside TSH 164 
measurement (point-of-care test or POCT) by a health worker attending the birth or visiting the 165 
mother and newborn soon after could potentially overcome the lack of NBS infrastructure. 166 
Although POCT technology for TSH measurement suitable for NBS is not currently available, it 167 
has already been developed and tested for sickle cell anemia [40], another major public health 168 
problem in many LMICs for which NBS appears cost-effective in pilot studies [41]. It is not yet 169 
clear how the POCT approach to NBS might be implemented on a population basis. As with 170 
centralized laboratory testing, POCT screening, if implemented as a public health program, would 171 
require quality assurance. Quality assurance could be facilitated through prompt transmittal of 172 
screen-positive results by cell phone to the relevant professionals and use of information 173 
technologies by public health authorities for regular audits of program performance. Importantly, 174 
NBS is just the beginning of a process that leads to confirmation of the diagnosis of CH and ideally 175 
of its etiology, adequate continuous treatment and documentation of outcomes [42]. All of these 176 
downstream aspects of NBS are particularly a challenge in LMICs. 177 
In conclusion, the costs of NBS for overt CH are clearly justified by the ensuing benefits. 178 
However, the full achievement of the benefits of NBS requires prompt follow-up and initiation of 179 
treatment along with continued monitoring and lifelong treatment for individuals with permanent 180 
CH. 181 
Congenital Adrenal Hyperplasia (CAH) 182 
NBS for classic CAH due to 21-hydroxylase deficiency, a condition with a prevalence in 183 
high-income countries of about one in 18,000, both before and after NBS [8], was first proposed 184 
in 1977 with the primary objective of preventing the death of affected boys [43]. Many historical 185 
case series had shown a marked female predominance [44]. Because the mode of inheritance of 186 
CAH is autosomal recessive, this imbalance likely reflected underdiagnosis of affected boys, since 187 
in contrast to genetic females, their external genitalia are unambiguous and there is no clinical clue 188 
to the diagnosis at birth. Increased clinical recognition has led to the expected Mendelian ratio of 189 
males and females, even in the absence of NBS [45], including in middle-income countries, such 190 
as Brazil [46]. Losing a newborn because the diagnosis of an eminently treatable disease has not 191 
been made is a tragedy for parents, which cannot be expressed in monetary terms [47]. Fortunately, 192 




this tragedy has become exceptional in high income countries [8], although it still occurs in a few 193 
cases, even where NBS has been implemented [48]. Regardless of NBS, healthcare professionals 194 
caring for newborns should think of this diagnosis in cases of dehydration or insufficient weight 195 
gain, a very sensitive indicator of the severe, potentially fatal salt-wasting form of CAH [49]. 196 
Another often quoted argument in favor of NBS for CAH is to “avoid misassignment” of 197 
a fully virilized genetic female newborn to a male sex, which can also lead to genital surgical 198 
reconstruction. However, this major and contentious challenge for parents is not “avoided” by 199 
NBS. Rather, in the majority of these cases, genetic sex is established a few days earlier than it 200 
would be when a salt-wasting crisis leads to the diagnosis. 201 
Screening for CAH using 17-hydroxyprogesterone (17OHP) as the biomarker was 202 
implemented in New Zealand and some US states and Canadian provinces in the early 1980s but 203 
was not universally recommended in France until 1995 and in the USA until 2005. Over time, 204 
NBS for CAH has been gradually implemented in most high-income countries, with holdouts 205 
including the United Kingdom [50] and some Australian states and Canadian provinces [45]. 206 
Two published CEAs of NBS for CAH in the USA yielded conflicting results as to whether 207 
NBS would be considered cost-effective relative to other preventive strategies [51, 52]. The two 208 
studies assumed different probabilities of death in the absence of NBS [8, 53], with the less 209 
favorable cost-effectiveness results reflecting an evidence-based assessment of mortality data 210 
suggesting that no more than 3% of infants with CAH in high-income countries die in the absence 211 
of NBS versus an infant mortality rate of 10% assumed in the other CEA. An erratum to the second  212 
CEA concluded that, even correcting for calculation problems, NBS for CAH would not meet 213 
conventional cost-effectiveness criteria [54]. The less favorable cost-effectiveness findings on 214 
NBS for CAH relative to CH reflect the very small number of potentially preventable deaths from 215 
this rare disorder in high-income countries, even taking into account the preventable costs of 216 
hospitalizations due to salt-wasting crises [53]. Nonetheless, decisions on screening for particular 217 
disorders are primarily determined on the basis of better outcomes for affected children, not 218 
considerations of economic benefits [27]. 219 
Newer economic evaluations of NBS for CAH have explored two additional avenues for 220 
showing economic value. First, a Canadian study reported greater preventable hospitalization costs 221 
than previously reported but assumed no reduction in mortality with NBS [55]. Second, even 222 
though relatively few children with clinically diagnosed CAH experience neurocognitive effects 223 
similar to those that were observed in CH before NBS [45, 56], two economic evaluations of NBS 224 
for CAH, an unpublished study from Australia and a recently published study from Brazil, have 225 
modeled reductions in neurocognitive impairment as an expected benefit [53]. The Brazilian study 226 
provided supporting evidence of an excess rate of neurological impairment in children with CAH 227 
in that country [46]. The magnitude of benefit of NBS may be more evident in LMICs because of 228 
limited access to qualified professionals, a higher neonatal mortality or more severe neonatal 229 
morbidity from CAH [46]. An interesting question is whether more thorough education of 230 
professionals might achieve the primary objective of screening, to prevent the death of affected 231 
boys, possibly at a lower cost than with NBS [44]. 232 




Although NBS for CAH is recommended by expert opinion [57], the lack of its universal 233 
implementation may result from questions about its rationale, different priorities in expanding 234 
NBS and the rarity of severe outcomes. One challenge is the short turnaround time required for 235 
reporting results, especially if the blood spots are collected late in the first week of life (as is the 236 
case in the UK), since death from a salt-wasting crisis can occur as early as day 8 [47]. Another 237 
challenge is the very low (<10%) PPV of 17OHP [58, 59], the biomarker used as first-tier screening 238 
for CAH. Elevated 17OHP is frequent in children born prematurely, but since CAH is not 239 
frequently observed in premature infants [45], a different strategy in this subgroup may be 240 
warranted [48]. The PPV of screening for CAH can be improved by adding other biomarkers or 241 
repeat specimens. Although second-tier screening increases costs, the reduction in false-positive 242 
screening results may justify the added expenditure. For example, the New South Wales screening 243 
program in Australia recently reported a PPV of 71% for 17OHP immunoassay screening of 244 
specimens collected at 48-72 hours followed by steroid profiling using liquid chromatography 245 
tandem mass spectrometry of specimens in the top 2% of 17OHP values by birthweight as well as 246 
repeat specimens for first-tier positive screens [60]. The program notified providers of presumptive 247 
results in all cases by day 9, prior to the occurrence of any adrenal crisis among the 10 infants 248 
identified with CAH. These recent developments may lead to the universal adoption of NBS for 249 
CAH. 250 
Conclusion 251 
The individual and societal-level health and economic benefits of NBS for permanent CH 252 
have been clearly demonstrated, which is why CH is typically among the first disorders for 253 
newborn screening to be established. The economic benefits of NBS for CH may have been 254 
incompletely calculated, i.e., understated, by not taking into account changes in the overall 255 
distribution of cognitive and behavioral endpoints. On the other hand, some newborns, especially 256 
those born preterm, have transient hyperthyrotropinemia and are currently identified with CH and 257 
treated with levothyroxine, the benefits of which are unclear. It has been argued that this can result 258 
in overdiagnosis of CH and the undue medicalization of a large number of premature infants [61], 259 
which future economic analyses of NBS might consider [62]. The economic benefits of NBS for 260 
CAH are ambiguous, as mortality has become very rare in high income countries and a causal 261 
relationship between the initial dehydration episode and neurocognitive sequelae has not been 262 
established [53]. 263 
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Table. Comparison of economic analyses of NBS for primary CH and classic CAH 266 
Disease CH CAH 
Prevalence before NBS 1/6,500 1/18,000 
Prevalence after NBS 1/2,000 or more 1/18,000 
Benefits of NBS Normalizes IQ in all -Prevents neonatal deaths 
-Shortens initial hospital stay 
-Shortens duration of sex 
misassignment 
PPV of biomarker 95% for TSH > 30 mU/L 1-10% for 17OHP > 50 nmol/L 
Savings (per US $ spent on 
NBS) 
2 $ or more 
(negative net cost) 
<1 $ 
(positive net cost) 
Gain of IQ among children 
with permanent CH 
(prevalence of 1 in 4,500 in 
Swedish study by Alm et al. 
1984) [12] 
Variable impact of timely 
treatment – mean increase 
of 16 IQ points 
(range 7-55) 
NA 
ICER (if positive net cost) NA Less than USD 150,000 per life-
year saved 
CAH – congenital adrenal hyperplasia 267 
CH – congenital hypothyroidism 268 
ICER – incremental cost-effectiveness ratio 269 
IQ – intelligence quotient 270 
NA – not applicable 271 
NBS – newborn screening 272 
PPV – positive predictive value 273 
TSH – thyroid stimulating hormone274 
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